Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568555 | 1.00 | ALDH1A1 (0.33) | ALDH1A1GRM4RXRAGRIN1GRIN2B | |
| SCHEMBL29739679 | 0.91 | ALDH1A1 (0.33) | ALDH1A1RXRAGRIN1GRIN2BKMT2A | |
| Hydrochloric Acid SCHEMBL9528320 | 0.87 | RXRA (0.32) | GRM4RXRAGRIN1GRIN2BKMT2A | |
| SCHEMBL25009946 | 0.84 | KMT2A (0.32) | ALDH1A1KMT2A | |
| SCHEMBL24696890 | 0.82 | BACE1 (0.37) | ALDH1A1KMT2A | |
| SCHEMBL24696677 | 0.82 | GAA (0.38) | ALDH1A1RXRAGRIN1GRIN2BKMT2A | |
| SCHEMBL23012404 | 0.82 | POLB (0.35) | ALDH1A1KMT2A | |
| SCHEMBL30892374 | 0.82 | GAA (0.38) | ALDH1A1RXRAGRIN1GRIN2BKMT2A | |
| SCHEMBL14453810 | 0.81 | TLR8 (0.36) | ALDH1A1 | |
| SCHEMBL30977552 | 0.80 | GAA (0.46) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296931-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4619402-A1 | GPR17 MODULATORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12358875-B2 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis | UCB PHARMA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| EP-4558483-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119613397-A | N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors | 迈巴制药(南京)有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119546576-A | Novel isoquinolinones pyrrolo-pyridones and thieno pyridone sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
| WO-2024104462-A1 | GPR17 MODULATORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-05-23 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024017857-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-3983384-B1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-3983384-B1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| US-20220298112-A1 | N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis | UCB PHARMA GMBH (DE) | 2022-09-22 | — | — | US | disclosed |
| EP-3983384-A1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB Pharma GmbH (DE) | 2022-04-20 | — | — | EP | disclosed |
| CN-113993845-A | N- (phenyl) -indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for the treatment of CNS disorders, such as multiple sclerosis | 优时比制药有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020254289-A1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254289-A1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298112-A1 | N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis | GPR27, GPR18, GPR17 | ALDH1A1 2081/4885GRM4 53/4885RXRA 729/4885 |
| US-20250296931-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | SULT1E1, XDH, PRXL2A | ALDH1A1 1934/4885GRM4 2681/4885RXRA 1613/4885 |
| US-12358875-B2 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis | GPR27, GPR18, GPR17 | ALDH1A1 2081/4885GRM4 53/4885RXRA 729/4885 |
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | GPR3, GPR27, GPR65 | ALDH1A1 3504/4885GRM4 113/4885RXRA 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.